Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru

International Journal of Infectious Diseases

Volumn 12, Issue 3, 2008, Pages 325-331

  López de Castilla, Diego ^a   Verdonck, Kristien ^a,b   Otero, Larissa ^a   Iglesias, David ^a   Echevarría, Juan ^a,c   Lut, Lynen ^b,d   Gotuzzo, Eduardo ^a,c   Seas, Carlos ^a,c  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b Retrovirology Research Unit   (Belgium)

^c HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

CD4+ lymphocytes; Highly active antiretroviral therapy

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PERU; SIDE EFFECT; TREATMENT FAILURE; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HOSPITALS, PUBLIC; HUMANS; MALE; NATIONAL HEALTH PROGRAMS; PERU; PREDICTIVE VALUE OF TESTS; VIRAL LOAD;

EID: 42149189032     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.09.008     Document Type: Article

References (40)

1. Sterne J.A., Hernan M.A., Ledergerber B., Tilling K., Weber R., Sendi P., et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366 (2005) 378-384
2. Egger M., May M., Chene G., Phillips A.N., Ledergerber B., Dabis F., et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 (2002) 119-129
3. Hogg R.S., Yip B., Kully C., Craib K.J., O'Shaughnessy M.V., Schechter M.T., et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 160 (1999) 659-665
4. Mocroft A., Vella S., Benfield T.L., Chiesi A., Miller V., Gargalianos P., et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352 (1998) 1725-1730
5. UNAIDS Report for 2003: most deaths and new infections ever; some good news. Aids Treat News 2003;(396):3.
6. Kuehn B.M. UNAIDS report: AIDS epidemic slowing, but huge challenges remain. JAMA 296 (2006) 29-30
7. The Global Fund to Fight AIDS Tuberculosis and Malaria. Monthly progress update. 31 August 2007. Available at: http://www.theglobalfund.org/en/files/publications/basics/progress_update/progressupdate.pdf (accessed October 2007).
8. Braitstein P., Brinkhof M.W., Dabis F., Schechter M., Boulle A., Miotti P., et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367 (2006) 817-824
9. Ministerio de Salud del Peru. Dirección General de Epidemiología. Situación del VIH-SIDA en el Perú. Boletín Epidemiológico Mensual, May 2007. Available at: http://www.oge.sld.pe/vigilancia/vih/Boletin_2007/mayo.pdf (accessed July 2007).
10. World Health Organization. TB/HIV Working Group of the Global Partnership to Stop TB and UNAIDS/WHO Working Group on Global HIV/AIDS/STI Surveillance. Guidelines for HIV Surveillance among tuberculosis patients; 2004. WHO/HTM/TB/2004.339. Available at: http://www.who.int/tb/publications/2004/en/ (accessed October 2007).
11. UNAIDS. Uniting the World Against AIDS. Country situation analysis - Peru. Available at: http://www.unaids.org/en/Regions_Countries/Countries/peru.asp (accessed July 2007).
12. NIMH Collaborative HIV/STD Prevention Trial Group. Sexually transmitted disease and HIV prevalence and risk factors in concentrated and generalized HIV epidemic settings. AIDS 21 Suppl 2 (2007) S81-S90
13. Gotuzzo E, Seas C, Echevarría J, Samalvides F, Maguiña C, Verdonck K, et al. Trends in characteristics of HIV-seropositive patients attended in a public hospital in Peru from 1985 to 2003. XV International AIDS Conference, Bangkok, 11-16 July 2004. Abstract book 2004; 1:127, abstract MoPeC3534.
14. Lama J.R., Sanchez J., Suarez L., Caballero P., Laguna A., Sanchez J.L., et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 42 (2006) 501-505
15. Dragsted U.B., Mocroft A., Vella S., Viard J.P., Hansen A.B., Panos G., et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 190 (2004) 148-155
16. Hogg R.S., Bangsberg D.R., Lima V.D., Alexander C., Bonner S., Yip B., et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 3 (2006) 1570-1578
17. Kilaru K.R., Kumar A., Sippy N., Carter A.O., and Roach T.C. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Med 7 (2006) 99-104
18. Lawn S.D., Myer L., Bekker L.G., and Wood R. CD4+ cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 6 (2006) 59
19. Echevarría J., Lopez de Castilla D., Seas C., Verdonck K., and Gotuzzo E. Scaling-up HAART in Peru: problems on the horizon. J Acquir Immune Defic Syndr 43 (2006) 625-626
20. Ministerio de Salud del Peru. Norma tecnica para el tratamiento antiretroviral de gran actividad - TARGA - en adultos infectados por el virus de la inmunodeficiencia humana. MINSA/DGSP-V.01; 2004. Available at: http://www.minsa.gob.pe/portal/03Estrategias-Nacionales/03ESN-ITS-SIDA/esn-vihbl.asp (accessed October 2007).
21. Calmy A., Pinoges L., Szumilin E., Zachariah R., Ford N., and Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20 (2006) 1163-1169
22. Gandhi R.T., Spritzler J., Chan E., Asmuth D.M., Rodriguez B., Merigan T.C., et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 42 (2006) 426-434
23. Mocroft A., Devereux H., Kinloch-de-Loes S., Wilson D., Madge S., Youle M., et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 14 (2000) 1545-1552
24. Tassie J.M., Szumilin E., Calmy A., and Goemaere E. Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières. AIDS 17 (2003) 1995-1997
25. May M.T., Sterne J.A., Costagliola D., Sabin C.A., Phillips A.N., Justice A.C., et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368 (2006) 451-458
26. Ivers L.C., Kendrick D., and Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41 (2005) 217-224
27. Autran B., Carcelain G., Li T.S., Blanc C., Mathez D., Tubiana R., et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 227 (1997) 112-116
28. Kaufmann G.R., Bloch M., Zaunders J.J., Smith D., and Cooper D.A. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 14 (2000) 959-969
29. Kaufmann G.R., Bloch M., Finlayson R., Zaunders J., Smith D., and Cooper D.A. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4+ T lymphocyte response to potent antiretroviral therapy. AIDS 16 (2000) 359-367
30. Pakker N.G., Notermans D.W., de Boer R.J., Roos M.T., de Wolf F., Hill A., et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 4 (1998) 208-214
31. Eron J.J., Murphy R.L., Peterson D., Pottage J., Parenti D.M., Jemsek J., et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 14 (2000) 1601-1610
32. Foudraine N.A., de Jong J.J., Jan W.G., van Benthem B.H., Maas J., Keet I.P., et al. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS 12 (1998) 1513-1519
33. Joly V., Flandre P., Meiffredy V., Brun-Vezinet F., Gastaut J.A., Goujard C., et al. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial). Antimicrob Agents Chemother 46 (2002) 1906-1913
34. Kuritzkes D.R., Marschner I., Johnson V.A., Bassett R., Eron J.J., Fischl M.A., et al. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. AIDS 13 (1999) 685-694
35. Molina J.M., Cheuc G., Ferchal F., Journot V., Pellegrin I., Sombardier M.N., et al. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients. Antivir Ther 4 Suppl 3 (1994) 71-74
36. Rouleau D., Conway B., Raboud J., Rae S., Fransen S., Shillington A., et al. Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study. J Infect Dis 176 (1997) 1156-1160
37. Squires K.E., Gulick R., Tebas P., Santana J., Mulanovich V., Clark R., et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 14 (2000) 1591-1600
38. Lawn S.D., Myer L., Harling G., Orrell C., Bekker L.G., and Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 43 (2006) 770-776
39. Kaufmann G.R., Perrin L., Pantaleo G., Opravil M., Furrer H., Telenti A., et al. CD4+ T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 163 (2003) 2187-2195
40. Viard J.P., Mocroft A., Chiesi A., Kirk O., Roge B., Panos G., et al. Influence of age on CD4+ cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 183 (2001) 1290-1294